- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
Wall Street Zen Upgrades Regeneron Pharmaceuticals to 'Buy'
Analysts see growth potential for biotech company's drug pipeline
Mar. 28, 2026 at 5:25am
Got story updates? Submit your updates here. ›
Wall Street Zen, a financial research firm, has upgraded its rating on Regeneron Pharmaceuticals (NASDAQ:REGN) from 'hold' to 'buy', citing the company's promising drug development pipeline and growth prospects.
Why it matters
Regeneron is a major player in the biotech industry, known for its innovative drug discovery technologies. An upgrade from a respected research firm like Wall Street Zen could signal increased investor confidence in the company's future performance and ability to bring new treatments to market.
The details
In its report, Wall Street Zen cited Regeneron's strong pipeline of drug candidates, including several in late-stage clinical trials, as a key factor behind the upgrade. The firm also noted the company's solid financial position and history of successful drug launches.
- Wall Street Zen issued the upgrade report on Saturday, March 28, 2026.
The players
Wall Street Zen
A financial research firm that provides analysis and ratings on publicly traded companies.
Regeneron Pharmaceuticals
A U.S.-based biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious medical conditions.
What they’re saying
“Regeneron's strong pipeline of drug candidates, combined with its financial stability and track record of successful launches, make it an attractive investment opportunity at this time.”
— Wall Street Zen Analyst, Research Analyst
What’s next
Investors will be closely watching Regeneron's upcoming clinical trial results and regulatory filings as the company continues to advance its drug pipeline.
The takeaway
The Wall Street Zen upgrade underscores the growing confidence in Regeneron's ability to maintain its position as a leading innovator in the biotech industry and deliver value for shareholders.
